How PBMs Use Scale to Lower Drug Costs for Americans

Prescription drugs are one of the fastest-growing cost pressures in American health care. For families, employers, and public programs, drug spending affects premiums, out-of-pocket costs, and access to care. Behind the scenes, pharmacy benefit managers (PBMs) play a central role in how those prices are set—and scale is the mechanism that gives them leverage.

PBMs aggregate demand across millions of patients, thousands of employers, and public programs. That aggregation turns fragmented purchasing into a coordinated market force. The result is lower net prices, broader access, and more predictable spending.

PBMs Operate the Purchasing Layer

Drug pricing is not determined at the pharmacy counter. It is shaped upstream through negotiations over formularies, rebates, and access. PBMs sit at this purchasing layer. They design formularies, negotiate discounts, and manage utilization on behalf of insurers and employers.

Scale matters because manufacturers respond to volume. When a PBM represents tens of millions of covered lives, placement on a formulary translates into significant market access. That access has value. PBMs use it to secure lower net prices and concessions that smaller purchasers could not obtain independently.

Aggregation Turns Demand Into Leverage

Most employers and health plans are too small to negotiate effectively on their own. Each would face higher prices and weaker terms if they approached the market separately. PBMs aggregate those buyers into a single negotiating entity.

This aggregation creates a credible alternative for manufacturers: compete for preferred placement or accept reduced access. The negotiating power does not come from regulation or mandates. It comes from consolidated demand.

Large PBMs operate at a scale that allows them to extract savings that are then reflected in premiums and plan costs.

Formularies as Cost-Control Tools

Formularies are often misunderstood as limitations. In practice, they are negotiating tools. By organizing drugs into tiers and setting coverage rules, PBMs create incentives that favor lower-cost options when clinically appropriate.

Preferred placement drives volume. Volume drives discounts. Those discounts reduce the net cost paid by plans and employers. Without scale, formularies lose their power. With scale, they shape pricing across the market.

This structure also supports competition among therapeutically similar drugs. Manufacturers compete for placement, which puts downward pressure on prices.

Rebates and Net Prices

Public debate often focuses on list prices. Net prices—the prices paid after negotiated discounts and rebates—tell a more accurate story. PBMs negotiate rebates tied to access and utilization, which reduce the effective cost of drugs to plans.

Scale increases the size and reliability of these rebates. Large PBMs can commit to volume, enforce utilization management, and ensure compliance across networks. Smaller purchasers cannot offer the same certainty, and therefore receive weaker terms.

The savings generated at this level are used to offset premiums, fund benefits, and stabilize plan costs.

Managing Utilization at Scale

Lower prices are only part of cost control. Utilization matters. PBMs invest in clinical management programs that guide appropriate use, reduce duplication, and encourage adherence. These programs are expensive to build and maintain.

Scale spreads those costs across large populations, making sophisticated management economically viable. Better utilization reduces waste, improves outcomes, and limits unnecessary spending that would otherwise raise costs for everyone.

Stability for Employers and Public Programs

Employers and public payers depend on predictability. Sudden spikes in drug spending translate into higher premiums or reduced benefits. PBMs provide budget stability by locking in pricing terms, managing formularies, and smoothing volatility.

Scale enables long-term contracts and standardized processes. That stability benefits workers, retirees, and taxpayers who ultimately fund these plans.

Competition at the PBM Level

PBMs themselves compete for clients. Employers and insurers evaluate pricing guarantees, transparency terms, clinical outcomes, and service quality. This competition puts pressure on PBMs to pass through savings and innovate in benefit design.

Scale does not eliminate competition. It concentrates negotiating power upstream while maintaining competition downstream among PBMs for customers.

Addressing Common Concerns

Skepticism around PBMs often centers on complexity and opacity. These are valid governance issues that warrant oversight and improvement. But complexity is a function of the market PBMs operate in, not evidence that scale fails to deliver savings.

Fragmenting purchasing power would weaken negotiating leverage and raise net prices. The more buyers act alone, the less pressure exists to lower costs.

The Broader Cost-of-Care Impact

Prescription drug costs ripple through the health system. Higher drug spending raises premiums and crowds out wages and benefits. Lower net prices ease pressure across the system.

PBMs, operating at scale, help translate purchasing power into savings that support affordability. Their role is structural. It is about how demand is organized in a market where individual buyers lack leverage.

The Bottom Line

Lower drug costs depend on negotiation power. Negotiation power depends on scale. PBMs aggregate demand, structure access, and manage utilization in ways that reduce net prices and stabilize spending.

This is not an abstract theory. It is how purchasing works in complex markets. When demand is coordinated, prices fall. When it is fragmented, prices rise.

For American families, employers, and public programs, scale at the PBM level remains one of the most effective tools for keeping prescription drug costs within reach.